A. Cheng

发表

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

R. Schooley, G. Beall, Michael D. Miller, 2002, AIDS.

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

A. Zolopa, H. Lampiris, S. Chuck, 2010, The Journal of infectious diseases.

A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents

K. White, S. Chuck, J. Pinto, 2012, The Pediatric infectious disease journal.

A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression

K. White, J. Church, S. Chuck, 2015, The Pediatric infectious disease journal.

Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137

B. Kearney, A. Cheng, S. Ramanathan, 2007, Journal of acquired immune deficiency syndromes.

Speaker Abstracts

K. White, D. Ward, P. Sax, 2017, Journal of the International AIDS Society.

Drug‐Drug and Drug‐Food Interactions Between Tenofovir Disoproxil Fumarate and Didanosine

B. Kearney, Shan-Shan Chen, A. Cheng, 2005, Journal of clinical pharmacology.

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

J. Gallant, S. Staszewski, J. Hulot, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment

F. Post, A. Cheng, C. Beraud, 2015, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir

R. Ebrahimi, A. Mathias, B. Kearney, 2006, Journal of acquired immune deficiency syndromes.

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients

J. Gallant, A. Pozniak, Shan-Shan Chen, 2008, AIDS.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

J. van Lunzen, M. Cavassini, C. Orkin, 2016, The Lancet. Infectious diseases.

Tenofovir, Equivalence, and Noninferiority—Reply

J. Gallant, S. Staszewski, A. Pozniak, 2004 .

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.

D. Podzamczer, A. Winston, M. Das, 2018, The lancet. HIV.

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

K. White, M. Johnson, K. Squires, 2016, The lancet. HIV.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

D. Ward, J. Gallant, M. Johnson, 2016, The lancet. HIV.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

F. Antunes, J. Gallant, J. Fehr, 2013, The Journal of infectious diseases.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment Week 144 Results

P. Sax, M. Das, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results

K. Tashima, P. Sax, M. Das, 2016, Journal of acquired immune deficiency syndromes.

Renal safety of tenofovir in HIV treatment-experienced patients

J. Hulot, H. Izzedine, A. Cheng, 2004, AIDS.

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

J. Rockstroh, J. Molina, A. Cheng, 2013, Journal of acquired immune deficiency syndromes.

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients

K. White, A. Cheng, M. Fordyce, 2014 .

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

K. White, A. Cheng, M. Fordyce, 2014, HIV clinical trials.

Absence of Clinically Relevant Pharmacokinetic Interaction Between Ribavirin and Tenofovir in Healthy Subjects

R. Ebrahimi, B. Kearney, A. Cheng, 2006, Journal of clinical pharmacology.

Evaluation of the HIV Lipodystrophy Case Definition in a Placebo-Controlled, 144-Week Study in Antiretroviral-Naive Adults

D. Cooper, M. Law, R. Puls, 2005, Antiviral Therapy.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

J. Gallant, M. Das, S. Oka, 2016, Journal of Acquired Immune Deficiency Syndromes.

Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens

K. White, C. Cohen, A. Cheng, 2013, HIV clinical trials.

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

K. White, J. Gallant, A. Cheng, 2017, Journal of acquired immune deficiency syndromes.

Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single‐tablet regimen for the treatment of HIV infection

B. Kearney, A. Cheng, S. Ramanathan, 2014, Journal of clinical pharmacology.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

M. Das, A. Clarke, P. Tebas, 2022 .

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

K. Lichtenstein, F. Post, Samir K. Gupta, 2016, Journal of acquired immune deficiency syndromes.

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

K. White, P. Sax, A. Zolopa, 2013, Journal of acquired immune deficiency syndromes.

Special Collection: A pioneer in antiviral drug discovery and development: Commemorating John Martin-Original Article

William A. Lee, A. Cheng, 2022 .

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

J. Gallant, E. Daar, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

J. Gallant, M. Das, P. Tebas, 2017, Journal of acquired immune deficiency syndromes.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

M. Das, J. Lelièvre, J. Slim, 2019, The lancet. HIV.

Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate

M. Wulfsohn, A. Cheng, N. Margot, 2004, Journal of acquired immune deficiency syndromes.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Joel E Gallant, Edwin DeJesus, Schlomo Staszewski, 2004, JAMA.

Resistance development over 144 weeks in treatment‐naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 *

M. D. Miller, A. Cheng, B. Lu, 2006, HIV medicine.

Extended Treatment With Tenofovir Disoproxil Fumarate in Treatment‐Experienced HIV‐1‐Infected Patients: Genotypic, Phenotypic, and Rebound Analyses

I. McGowan, Erica Isaacson, A. Cheng, 2003, Journal of acquired immune deficiency syndromes.

Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration

Ramin Ebrahimi, R. Ebrahimi, B. Kearney, 2005, Journal of clinical pharmacology.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Joel E Gallant, Edwin DeJesus, B. Gazzard, 2006, The New England journal of medicine.

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

D. Cooper, G. Dore, A. Pozniak, 2004, The Journal of infectious diseases.

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF

R. Schooley, I. McGowan, Erica Isaacson, 2002, AIDS.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.

Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

Brian P. Kearney, Calvin Cohen, Edwin DeJesus, 2006, Journal of acquired immune deficiency syndromes.

The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients

A. Cheng, Lijie Zhong, J. Enejosa, 2007, HIV clinical trials.

Tenofovir alafenamide fumarate

A. Cheng, William A Lee, 2022, Antiviral therapy.

The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching Therapy

A. Cheng, C. Holmes, Lijie Zhong, 2007, HIV clinical trials.

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis

B. Gazzard, J. Gallant, J. Arribas, 2006, Journal of acquired immune deficiency syndromes.

Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data

D. Ward, R. Ebrahimi, A. Cheng, 2014, HIV clinical trials.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

K. White, J. Rockstroh, B. Kearney, 2012, The Lancet.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

K. White, P. Sax, A. Zolopa, 2012, The Lancet.

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

M. Wulfsohn, Shan-Shan Chen, A. Cheng, 2004, The Journal of infectious diseases.

Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents

A. Mathias, B. Kearney, A. Cheng, 2013, Journal of acquired immune deficiency syndromes.

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

M. Wulfsohn, K. Squires, A. Pozniak, 2003, Annals of Internal Medicine.

Background: Resistance to antiretroviral agents remains a lead- ing cause of treatment failure for patients infected with HIV-1.

M. Wulfsohn, K. Squires, A. Pozniak, 2003 .

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis

B. Gazzard, J. Gallant, J. Arribas, 2008, Journal of acquired immune deficiency syndromes.

Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934

A. Cheng, J. Enejosa, N. Margot, 2009, Journal of acquired immune deficiency syndromes.

A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

K. White, P. Sax, A. Zolopa, 2014, Journal of acquired immune deficiency syndromes.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

D. Podzamczer, K. White, J. Gallant, 2017, The Lancet.

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

K. White, D. Ward, P. Sax, 2017, The lancet. HIV.

Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults

A. Lazzarin, A. Rachlis, A. Cheng, 2015 .

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of Acquired Immune Deficiency Syndromes.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

K. White, H. Stellbrink, P. Sax, 2017, The Lancet.

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

D. Ward, P. Sax, A. Cheng, 2018, AIDS.

Pharmacokinetics of cobicistat boosted‐elvitegravir administered in combination with rosuvastatin

B. Kearney, A. Cheng, A. Ray, 2014, Journal of clinical pharmacology.

HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil

M. Lederman, D. Kuritzkes, K. White, 2013, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women

K. Squires, C. Kityo, A. Cheng, 2018, Journal of acquired immune deficiency syndromes.

Immunosuppressant Pharmacokinetics and Dosing Modifications in HIV‐1 Infected Liver and Kidney Transplant Recipients

L. Benet, P. Stock, A. Cheng, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

J. Rockstroh, E. Daar, J. Molina, 2018, The lancet. HIV.

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients

J. Gallant, S. Staszewski, A. Pozniak, 2004 .

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Bonaventura Clotet, A. LaMarca, B. Clotet, 2012, The Lancet. Infectious diseases.

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

T. Bannerman, M. Das, G. McComsey, 2016, EBioMedicine.

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3

A. Lazzarin, Y. Yazdanpanah, F. Post, 2017, HIV clinical trials.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.